rTMS in Treatment of Spasticity

ALS Clinical Trial

Official title:

TMS for Treatment of Spasticity in Patients With MND

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04054141
• Other study ID #: 2018-0434
• Status: Terminated
• Phase: N/A
• Start date: September 1, 2018
• Est. completion date: August 16, 2022

Study information

• Verified date: November 2022
• Source: Hospital for Special Surgery, New York
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label clinical trial to determine the safety and efficacy of rTMS in reducing spasticity and improving quality of life among patients with upper motor neuron predominant motor neuron disease (MND).

Description:

The study's objective is to evaluate the role of rTMS for symptom reduction of spasticity among patients with upper motor neuron predominant motor neuron disease. This study is 12-week open label safety and efficacy trial. A total of 10 subjects with PLS and UMN/ MND will be enrolled in this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: August 16, 2022
• Est. primary completion date: August 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Age = 18, men or woman
• Diagnosis of upper motor neuron predominant ALS, which also includes patients with primary lateral sclerosis (PLS), as defined as only upper motor neuron features in at least 2 body segments.
• EMG within 3 months of enrollment with minimal or no evidence of lower motor neuron disease.
• Time from symptom onset > 18 months
• On a stable dose of, or has not taken, Riluzole for at least thirty days.
• Has not taken, or has received at least 2 cycles of dosing of, Edaravone prior to screening.
• Able to communicate clearly the desire to withdraw from the procedure at any stage.
• Impaired walking as measured by a Hauser Ambulation index of greater than 1 and less than 7 (2 to 6, inclusive).
• MMSE = 22 and deemed by the PI as being capable of providing informed consent and following trial procedure.
• Has spasticity, equal or above 1 in the Ashworth Scale for spasticity in 2 or more muscle group of at least 3 months duration.
• Absence of exclusion criteria. Exclusion criteria
• Patient has a history of drug or alcohol abuse within the past year;
• Patient has clinically significant abnormal laboratory values.
• Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity
• Received Botulinum Toxin during the preceding 6 months
• Bedridden and patients with tracheostomy.
• Fixed-tendon contractures
• Poorly controlled epilepsy or recurrent seizures (Subjects who have had one or more seizures in the year prior to Visit 1 will be excluded)
• Unable to provide an informed consent
• Unable to comply with the procedures
• Unable to communicate clearly if the subject wants to withdraw from the procedure at any stage
• History of brain surgery for any indication
• Has pacemaker, cochlear implants, brain stimulators, infusion pumps, intracardiac lines, metallic clips, other implanted electronic or ferroelectric metallic devices above the neck (Dental implants are permitted), piercing or body modification above the neck, known history of TMS related complications or side effects.
• MMSE <22.
• Female patients of child bearing period who are not practicing contraception.
• Female patients who are pregnant.
• Inability to perform either rTMS due to insufficient MEP amplitude (< 50 µv).

Related Conditions & MeSH terms

• ALS
• Muscle Spasticity

Intervention

Device:
• Mag Stim
rTMS

Locations

Country	Name	City	State
United States	Shara Holzberg	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Hospital for Special Surgery, New York

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety of rTMS in subjects with PLS/UMN/MND. Number of participants with treatment related AE's will be measured with stringent stopping rules and reported. We hypothesize that no serious treatment related adverse event.	Transcranial magnetic stimulation is a non-invasive procedure used to stimulate small regions of the brain. The effect of rTMS on spasticity was studied in patients with stroke, MS, SCI and CP and found to be safe (4). There are no studies assessing safety of rTMS in patients with PLS and UMN/ MND with spasticity. Because it is so well tolerated in other diseases, we anticipate no adverse effects. However, we will systematically assess all adverse effects with stringent stopping rules for individual patients and the study. We hypothesize that no patient will have a serious treatment related adverse event. Therefore we will track the number of Participants With Treatment-Related AE as Assessed by CTCAE v4.0	from week 0 to the end of the study, an average of 5 months.
Secondary	To evaluate efficacy of rTMS using a modified FDA approved protocol in research subjects with PLS and UMN/MND.	The secondary objective of this study is to determine if rTMS causes an improvement in walking speed in patients with PLS and UMN/MND. This will be determined by evaluation of subject's walking speed during treatment and for period after the rTMS stimulation series has stopped. The primary end point will be measured through the consistent improvement in the Timed 25 Foot walk test (T25FW).	From week 0 to end of the study, an average of 5 months